April 1, 2024 07:09 AM EDT

Bristol Myers' Zeposia expansion plans hit by Phase 3 setback in Crohn's disease

Amber Tong

One of Bristol Myers Squibb’s top new immunology products has failed a Phase 3 study, denting hopes of growing the franchise through a new indication …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Bristol Myers' Zeposia expansion plans hit by Phase 3 setback in Crohn's disease

Amber Tong

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Biopharma begins to contemplate an RFK Jr.-influenced FDA if Trump wins

Pfizer shares new details on obesity pipeline, hints at ‘other opportunities’

GSK buys autoimmune T cell engager for $300M upfront from Chimagen

Novartis takes $800M MorphoSys writedown mere months after closing acquisition

Novartis highlights overall M&A track record following MorphoSys impairment

Following March inspection, Novo Nordisk's semaglutide manufacturing facility cited by FDA

Bris­tol My­er­s' Zeposia ex­pan­sion plans hit by Phase 3 set­back in Crohn's dis­ease

Sign up to read this article for free.

more like this

Viridian Therapeutics

Waltham, MA, USA

Bristol Myers' Zeposia expansion plans hit by Phase 3 setback in Crohn's disease